The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) who have previously failed a direct-acting antiviral (DAA)-containing regimen.